A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
188actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-09 | actual | When the study began enrolling |
| Primary completion | 2026-01-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-19 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: Eloralintide and Tirzepatide — also filed as LY3841136
- Drug: Eloralintide — also filed as LY3841136
Primary outcomes
what the primary-completion date above is the date OFCohorts A and B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide and Tirzepatide
measured Day 106 Predose to Approximately Week 26
Cohorts A and B: PK: Maximum Concentration (Cmax) of Eloralintide and Tirzepatide
measured Day 106 Predose to Approximately Week 26
Cohorts C and D: PK: AUC of Eloralintide and Tirzepatide
measured Baseline Up to Approximately Week 11
Cohorts C and D: PK: Cmax of Eloralintide and Tirzepatide
measured Baseline Up to Approximately Week 11
Cohorts E and F: PK: AUC of Eloralintide
measured Day 8 Predose Up to Approximately Week 12
Cohorts E and F: PK: Cmax of Eloralintide
measured Day 8 Predose Up to Approximately Week 12
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
measured Baseline Up to Approximately Week 26
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed